PetMed Express' (PETS) Sell (D) Rating Reaffirmed at Weiss Ratings

Key Points

• PetMed Express (PETS) has reaffirmed its "sell (d)" rating according to Weiss Ratings, indicating ongoing lack of confidence from analysts regarding its stock performance.
• Other analysts, including Zacks Research and Wall Street Zen, have varied recommendations, with ratings ranging from "hold" to "sell," contributing to an overall consensus price target of $3.20.
• In its latest quarterly earnings report, PetMed Express reported a significant loss of ($0.56) per share, missing estimates by ($0.60), highlighting challenges the company is currently facing.

PetMed Express (NASDAQ:PETS - Get Free Report)'s stock had its "sell (d)" rating restated by investment analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Other research analysts have also issued research reports about the stock. Zacks Research raised shares of PetMed Express from a "strong sell" rating to a "hold" rating in a research report on Monday, September 29th. Wall Street Zen cut shares of PetMed Express from a "hold" rating to a "sell" rating in a research note on Saturday, October 18th. One investment analyst has rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, PetMed Express has an average rating of "Sell" and a consensus price target of $3.20.

PetMed Express Price Performance

NASDAQ PETS opened at $2.74 on Friday. PetMed Express has a 12 month low of $2.42 and a 12 month high of $6.85. The firm has a market capitalization of $57.59 million, a PE ratio of -9.13 and a beta of 0.73. The company's 50 day simple moving average is $2.78 and its 200 day simple moving average is $3.22.

PetMed Express (NASDAQ:PETS - Get Free Report) last posted its quarterly earnings data on Tuesday, October 14th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.60). The firm had revenue of $46.47 million for the quarter. PetMed Express had a negative return on equity of 6.76% and a negative net margin of 2.76%. Sell-side analysts anticipate that PetMed Express will post 0.19 earnings per share for the current fiscal year.

Insider Activity at PetMed Express

In related news, major shareholder Silvercape Investments Ltd bought 101,000 shares of PetMed Express stock in a transaction that occurred on Wednesday, August 13th. The stock was acquired at an average price of $3.17 per share, with a total value of $320,170.00. Following the acquisition, the insider owned 2,579,696 shares of the company's stock, valued at approximately $8,177,636.32. This represents a 4.07% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.10% of the company's stock.

Institutional Trading of PetMed Express

Institutional investors have recently bought and sold shares of the business. R Squared Ltd acquired a new position in shares of PetMed Express in the 2nd quarter valued at approximately $34,000. Goldman Sachs Group Inc. raised its position in shares of PetMed Express by 59.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 33,209 shares of the company's stock valued at $139,000 after buying an additional 12,360 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of PetMed Express in the 2nd quarter valued at approximately $51,000. Oxford Asset Management LLP acquired a new position in shares of PetMed Express in the 2nd quarter valued at approximately $55,000. Finally, Bridgeway Capital Management LLC increased its position in PetMed Express by 96.2% during the 2nd quarter. Bridgeway Capital Management LLC now owns 40,800 shares of the company's stock worth $135,000 after purchasing an additional 20,000 shares in the last quarter. Institutional investors own 73.33% of the company's stock.

PetMed Express Company Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.